JPS6312445B2 - - Google Patents
Info
- Publication number
- JPS6312445B2 JPS6312445B2 JP56157925A JP15792581A JPS6312445B2 JP S6312445 B2 JPS6312445 B2 JP S6312445B2 JP 56157925 A JP56157925 A JP 56157925A JP 15792581 A JP15792581 A JP 15792581A JP S6312445 B2 JPS6312445 B2 JP S6312445B2
- Authority
- JP
- Japan
- Prior art keywords
- gypenosides
- gypenoside
- active
- glc
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 239000002246 antineoplastic agent Substances 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 210000000988 bone and bone Anatomy 0.000 claims description 4
- OORMXZNMRWBSTK-UHFFFAOYSA-N dammaran Natural products C1CCC(C)(C)C2CCC3(C)C4(C)CCC(C(C)CCCC(C)C)C4CCC3C21C OORMXZNMRWBSTK-UHFFFAOYSA-N 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 229930187479 gypenoside Natural products 0.000 description 46
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- FBFMBWCLBGQEBU-RXMALORBSA-N (2s,3r,4s,5s,6r)-2-[(2r,3r,4s,5s,6r)-2-[[(3s,5r,6s,8r,9r,10r,12r,13r,14r,17s)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2s)-6-methyl-2-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhept-5-en-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecah Chemical class O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FBFMBWCLBGQEBU-RXMALORBSA-N 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 26
- ZRBFCAALKKNCJG-UHFFFAOYSA-N gypenoside-XVII Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OC(CO)C(O)C(O)C1O ZRBFCAALKKNCJG-UHFFFAOYSA-N 0.000 description 19
- 239000000203 mixture Substances 0.000 description 17
- 239000000284 extract Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 9
- 240000006509 Gynostemma pentaphyllum Species 0.000 description 8
- 150000001721 carbon Chemical group 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241000196324 Embryophyta Species 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000002504 physiological saline solution Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 5
- 208000002495 Uterine Neoplasms Diseases 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 201000007270 liver cancer Diseases 0.000 description 5
- 208000014018 liver neoplasm Diseases 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 208000020816 lung neoplasm Diseases 0.000 description 5
- 206010046766 uterine cancer Diseases 0.000 description 5
- 206010003445 Ascites Diseases 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 4
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 229930182490 saponin Natural products 0.000 description 4
- 150000007949 saponins Chemical class 0.000 description 4
- 235000017709 saponins Nutrition 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical group O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- OORMXZNMRWBSTK-LGFJJATJSA-N dammarane Chemical group C1CCC(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@H]([C@H](C)CCCC(C)C)[C@H]4CC[C@@H]3[C@]21C OORMXZNMRWBSTK-LGFJJATJSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- YERVVNJJSVYXJR-UHFFFAOYSA-N Gypenoside XXII Natural products C1CC(C2(C)C(C3(CCC(C(C)(C)C3CC2)OC2C(C(O)C(O)C(CO)O2)OC2C(C(O)C(O)C(CO)O2)O)CO)CC2)(C)C2C1C(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O YERVVNJJSVYXJR-UHFFFAOYSA-N 0.000 description 2
- 241001316290 Gypsophila Species 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- RTBXOFMHEMBXKG-UHFFFAOYSA-N 2-methyl-1,2-dihydrobenzo[j]aceanthrylene Chemical compound C1=CC2=CC=CC=C2C2=C1C(CC(C1=CC=C3)C)=C1C3=C2 RTBXOFMHEMBXKG-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- KHPWSKNLAFECBO-NSMVKXLTSA-N Gypenoside XXV Chemical compound C([C@](O)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C)[C@@H]([C@]4(CC[C@@H](C(C)(C)[C@@H]4CC3)O[C@H]3[C@@H]([C@@H](O)[C@@H](O)CO3)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C=O)CC2)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O KHPWSKNLAFECBO-NSMVKXLTSA-N 0.000 description 1
- IROUVKVGJYDVOC-UHFFFAOYSA-N Gypenoside XXVI Natural products C1CC(C2(C)C(C3(CCC(C(C)(C)C3CC2)OC2C(C(O)C(O)CO2)OC2C(C(O)C(O)C(CO)O2)O)C=O)CC2)(C)C2C1C(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O IROUVKVGJYDVOC-UHFFFAOYSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000002021 butanolic extract Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 235000021050 feed intake Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- DOUGLYJWNNDEQP-UHFFFAOYSA-N gypenoside XXVIII Natural products CC(=CCCC(C)(O)C1CCC2(C)C1CCC3C2(C)CCC4C(C)(C)C(CCC34C=O)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C DOUGLYJWNNDEQP-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- -1 liquid paraffin Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56157925A JPS5859921A (ja) | 1981-10-02 | 1981-10-02 | アマチヤヅルサポニンを含有する抗癌剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP56157925A JPS5859921A (ja) | 1981-10-02 | 1981-10-02 | アマチヤヅルサポニンを含有する抗癌剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5859921A JPS5859921A (ja) | 1983-04-09 |
| JPS6312445B2 true JPS6312445B2 (zh) | 1988-03-18 |
Family
ID=15660457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP56157925A Granted JPS5859921A (ja) | 1981-10-02 | 1981-10-02 | アマチヤヅルサポニンを含有する抗癌剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5859921A (zh) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991001139A1 (de) * | 1989-07-21 | 1991-02-07 | Marigen S.A. | Sterole, deren fettsäureester und glucoside; verfahren zu ihrer herstellung; spontan dispergierbare mittel mit diesen verbindungen, sowie ihre verwendung zur behandlung von tumoren |
| GB9518883D0 (en) * | 1995-09-15 | 1995-11-15 | Leo Pharm Prod Ltd | Chemical compounds |
| KR101128920B1 (ko) | 2009-12-15 | 2012-04-23 | 충남대학교산학협력단 | 지페노사이드, 이의 제조방법 및 용도 |
| CN102579471B (zh) * | 2012-01-16 | 2013-12-11 | 中央民族大学 | 四种绞股蓝皂苷类化合物制备治疗肿瘤药物的用途 |
| CN103012537B (zh) * | 2012-12-20 | 2014-10-29 | 上海交通大学 | 达玛烷型三萜类化合物及其制备方法和应用 |
| CN105153271B (zh) * | 2015-09-17 | 2018-03-02 | 沈阳农业大学 | 两个新的达玛烷型三萜类化合物及其制备方法和用途 |
| EP3501296A1 (en) * | 2017-12-22 | 2019-06-26 | Analyticon Discovery GmbH | Novel triterpene-glycosides as sweeteners or sweetener enhancer |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5857399A (ja) * | 1981-10-01 | 1983-04-05 | Osaka Chem Lab | ニンジンサポニン、その分離法及び製造法並びに用途 |
-
1981
- 1981-10-02 JP JP56157925A patent/JPS5859921A/ja active Granted
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5857399A (ja) * | 1981-10-01 | 1983-04-05 | Osaka Chem Lab | ニンジンサポニン、その分離法及び製造法並びに用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5859921A (ja) | 1983-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101035548B (zh) | 甾体皂苷药物组合物及其制备方法和应用 | |
| US6376682B1 (en) | Compound with α-glucosidase inhibiting action and method for producing the same | |
| CN111349017B (zh) | 一种从金钗石斛中提取化合物的工艺及应用 | |
| CN106220701A (zh) | 三萜化合物及其制备方法与应用 | |
| CN112168833A (zh) | 知母皂苷酶解产物及其主要组分知母皂苷aⅲ的医药用途 | |
| CN1210289C (zh) | 两头尖提取物的制备工艺和用途 | |
| CA2502703C (en) | A natural compound for prevention and treatment of diabetes, process for preparing the same, and pharmaceutical use thereof | |
| JPS6312445B2 (zh) | ||
| KR0169536B1 (ko) | 신규한 인삼 사포닌, 그의 제조방법 및 이를 유효성분으로 하는 항종양제 | |
| CN101537036A (zh) | 一种皂荚皂苷提取物及其制备方法与应用 | |
| CN116606269B (zh) | 米团花二倍半萜化合物与提取物l01及其在制药中的应用 | |
| CN102875615B (zh) | 大麻药苷a和大麻药总皂苷的提取方法及其应用 | |
| CN112961203B (zh) | 黄酮醇苷衍生物及其用途和制备方法 | |
| CN102988525A (zh) | 山楂核中总木脂素的制备方法及新用途 | |
| CN107513092B (zh) | 一种丙二酰基人参皂苷Rb1的制备方法及其医用用途 | |
| CN101099756B (zh) | 一种治疗肝癌的中药组合物及其制备方法和药物制剂 | |
| CN106977561B (zh) | Sutherlandin-5-p-hydroxybenzoate的制备及其在制备治疗类风湿关节炎药物中的应用 | |
| CN114436887B (zh) | 一种中药薏苡仁中的新生物碱及其提取纯化方法和应用 | |
| CN111675618B (zh) | 一种有柄石韦中的化合物及其分离纯化方法和应用 | |
| JPS6312448B2 (zh) | ||
| CN100546589C (zh) | 虫草头孢菌粉抗心律失常有效部位的制备及其药物制剂 | |
| JPS62132829A (ja) | 肝炎の治療剤 | |
| CN101392013A (zh) | 含有杂质人参皂苷Rh1的人参皂苷Rb1 | |
| CN101180065A (zh) | 用于预防和治疗2型糖尿病的包含知母皂苷a-ⅲ的组合物 | |
| JP4024128B2 (ja) | ウコギ科植物の花部の抽出物とその用途 |